Prominent players in the Vietnam Angina Market | Growth Insights 2026

Prominent players in the Vietnam Angina Market

Vietnam Angina Market is curated by a combination of major global players and domestic producers, each vying for a higher market share through product innovation and promotion of sustainable practices. Major companies in the market include Novartis, Sanofi, AstraZeneca, and Servier.

Vietnam Angina Market Overview

According to 6Wresearch, the Vietnam angina market is poised for development, determined by its versatile applications across the healthcare sector, including cardiology, emergency medicine, and chronic disease management. The market is particularly influenced by the increasing demand for natural and patient-centric treatment methods, as consumers focus towards effective oral therapies and life-saving interventions in personal care and home-based recovery.

Generally, angina products are specialized medical tools designed to manage the symptoms and underlying causes of chest pain resulting from reduced blood flow to the heart. These products appear as nitrate sprays, beta-blockers, calcium channel blockers, or advanced drug-eluting stents and are used extensively in clinical and homecare applications due to their myocardial oxygen demand reduction properties.

Competitive Landscape

The competitive landscape of the Vietnam angina industry is specified by the presence of several global giants, regional producers, and a rising number of emerging companies. Leading players have a significantly higher market share due to their longstanding presence in the pharmaceutical and medical device industries. They invest greatly towards research and development (R&D) to innovate and develop smart delivery systems and eco-friendly products to satisfy the increasing consumer demand for improved patient compliance.

Below is a list of leading players operating in the Vietnam Angina Market:

1. Novartis AG

Novartis is a global leader in cardiovascular health, providing innovative medications and various agents that helps in managing chronic stable angina.

2. Sanofi S.A.

Sanofi offers a broad portfolio of cardiovascular solutions, including antiplatelet therapies and calcium channel blockers used to prevent angina pectoris.

3. AstraZeneca plc

AstraZeneca is highly focused on the management of non-communicable diseases through its range of beta-blockers and anti-thrombotic medications.

4. Servier

Servier specializes in cardio metabolism and is well-known for its flagship anti-anginal product, which improves myocardial glucose utilization.

5. Pfizer Inc.

Pfizer provides essential cardiovascular medicines, including statins and calcium channel blockers that manage the risk factors associated with angina.

6. Medtronic

Medtronic leads the supply of drug-eluting stents and balloon angioplasty catheters used in surgical procedures to treat severe angina.

7. DHG Pharmaceutical JSC (DHG Pharma)

DHG Pharma manufactures a wide range of generic cardiovascular drugs and blood pressure medications tailored for the local market.

8. Traphaco JSC

Traphaco is known for its "Hoat Huyet Duong Nao" and other traditional medicine derived products that support circulatory health.

9. Stada Service Holding (STADA Pymepharco)

STADA produces high-quality European-standard generic cardiovascular treatments within Vietnam.

10. Vinphaco (Vinh Phuc Pharmaceutical JSC)

Vinphaco is a key domestic supplier of injectable and oral medications used in emergency cardiac care and long-term angina management.

Prominent players in the Vietnam Angina Market: FAQs